TY - JOUR
T1 - Topotecan and the treatment of recurrent ovarian cancer
T2 - is there a role for granulocyte colony-stimulating factor?
AU - Saltz, L.
AU - Janik, J. E.
PY - 1997/2
Y1 - 1997/2
N2 - Topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) a new chemotherapeutic agent for the treatment of patients with advanced carcinoma of the ovary after failure of initial or subsequent therapy, is a specific, potent inhibitor of the enzyme topoisomerase I. Myelosuppression is the dose-limiting toxicity of topotecan, and can interfere with the administration of the recommended dose/schedule of the drug by delaying the next cycle of chemotherapy or by requiring a reduction in the dose. The results from clinical studies suggest that routine granulocyte colony-stimulating factor therapy is not needed when topotecan is administered at the recommended dose of 1.5 mg/m2/d for 5 days. However, patients should be carefully monitored, as some may benefit from hematopoietic growth factor support on subsequent cycles.
AB - Topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) a new chemotherapeutic agent for the treatment of patients with advanced carcinoma of the ovary after failure of initial or subsequent therapy, is a specific, potent inhibitor of the enzyme topoisomerase I. Myelosuppression is the dose-limiting toxicity of topotecan, and can interfere with the administration of the recommended dose/schedule of the drug by delaying the next cycle of chemotherapy or by requiring a reduction in the dose. The results from clinical studies suggest that routine granulocyte colony-stimulating factor therapy is not needed when topotecan is administered at the recommended dose of 1.5 mg/m2/d for 5 days. However, patients should be carefully monitored, as some may benefit from hematopoietic growth factor support on subsequent cycles.
UR - http://www.scopus.com/inward/record.url?scp=0031064505&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031064505&partnerID=8YFLogxK
M3 - Review article
C2 - 9122740
AN - SCOPUS:0031064505
SN - 0093-7754
VL - 24
SP - S5-26-S5-2630
JO - Seminars in Oncology
JF - Seminars in Oncology
IS - 1 Suppl 5
ER -